ZIMMER BIOMET HOLDINGS, INC.
In the published model solve dated 2026-Q2, anchored at $100.91, ZIMMER BIOMET HOLDINGS, INC. (ZBH) is priced for +5.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• Zimmer Biomet is a leading maker of knee and hip implants plus surgical and robotics products, competing directly with the largest names in orthopedics, which its 10-K lists as ⟦"Johnson & Johnson MedTech... Stryker Corporation and Smith & Nephew plc."⟧ • The defining risk is execution against a soft setup: 2026 guidance is for organic revenue growth of just 1% to 3%, with up to 100 basis points of pricing erosion expected and a U.S. sales-force transition underway, while net debt sits near si
Is ZBH overvalued? See what's priced in →
886 institutional managers reported holding ZBH in 13F filings for the quarter ended 2026-03-31. 76 opened new positions that quarter. Held by Dodge & Cox, Vanguard Group, BlackRock, among others. On the short side, 11.7M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (5.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ZBH has cut its share count 9.2% over the past five years, spending $2.31B on repurchases. It pays a dividend, and has for 14 years running; the current rate is $0.96 a share annually. Cash returned over the past three years: $533.50M in dividends and $2.02B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ZBH over the trailing three years: 2023: 8 buys totaling $1.06M. 9 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ZBH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-02 | -7.1% | -14.6% |
| 2023-11-08 | -4.1% | +17.5% |
| 2024-02-24 | -3.7% | -7.6% |
| 2024-05-03 | +1.8% | -11.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ZBH's latest 8-K filings: 2026-08-05 (items 8.01, 9.01); 2026-08-05 (items 2.02, 9.01); 2026-06-29 (items 1.01, 1.02, 2.03, 9.01); 2026-05-27 (items 5.07, 9.01); 2026-05-12 (items 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.